Onconetix reported FY 2025 revenue of USD 0.82 million, down 68%, and cost of revenue of USD 0.18 million, down 88%. FY 2025 net loss narrowed 76% to USD 14.03 million, while loss from operations improved 68% to USD 17.86 million. FY 2025 selling, general and administrative expense fell 37% to USD 7.04 million, driven by lower payroll costs from headcount reductions and lower benefit costs following settlement of a defined benefit plan. The company recorded FY 2025 impairment of goodwill of USD 11.51 million, down 64%. Onconetix said it abandoned commercialization of ENTADFI and is focusing on commercializing Proclarix, while noting cash of USD 5.2 million at year-end and that it expects growing Proclarix revenues in 2026 and beyond.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-027725), on March 13, 2026, and is solely responsible for the information contained therein.